

# Proton Therapy beyond cancer: Potential benefits for neurodegenerative disorders

C.M. Coelho<sup>1,2,3</sup>, L. Pereira<sup>1,2,3</sup>, P. Teubig<sup>1,2</sup>, F. Murtinheira<sup>3</sup>, P. Santos<sup>4</sup>, F. Mendes<sup>4</sup>, S. Viñals<sup>5,6</sup>, D. Galaviz<sup>1,2</sup>, F. Herrera<sup>1,3</sup>

<sup>1</sup>FCUL, <sup>2</sup>LIP, <sup>3</sup>BioISI, <sup>4</sup>C2TN/IST, <sup>5</sup>CMAM/UAM, <sup>6</sup>UCM

IGFAE workshop on technologies and applied research at the future Galician proton-therapy facility


# OVERVIEW

- **Introduction and objectives**
- **Gamma-irradiations**
- **Proton beam**
  - Development of the IMP beam line for cell irradiation
  - Homogeneous irradiation for pT studies @ IMP
  - Proton irradiation of cells
- Future work
- Summary
- References

# INTRODUCTION

## Neurodegenerative disorders

- Increased prevalence
- **Progressive loss of neurons**
  - Unclear mechanisms
- **No cure**
- Histopathological hallmarks
  - Oxidative stress
  - Neuroinflammation
  - **Alterations in the homeostasis of proteins**





Most common degenerative cognitive diseases and their position in the brain (Hussain et al 2018)

➡ **Amyloids**

# Huntington Disease


- **Mutations** in exon 1 of the gene that encodes the Htt protein
  - **Abnormal long polyglutamine tract**
    - Greater expansion leads to a bigger aggregation of the **mutant form** of Htt



# Impact of LDRT in amyloidosis



- Antioxidant
- Anti-inflammatory
- DNA repair mechanism
- Tissue regeneration
- Cell proliferation



Improved cell viability  
 ↓ Aβ / Tau

Coelho et al 2022

# Impact of LDRT in amyloidosis



International Journal of  
*Molecular Sciences*



Review

## Radiation as a Tool against Neurodegeneration—A Potential Treatment for Amyloidosis in the Central Nervous System

Carina Marques Coelho <sup>1,2,†</sup> , Lia Pereira <sup>1,2,†</sup> , Pamela Teubig <sup>1</sup>, Pedro Santos <sup>3</sup> , Filipa Mendes <sup>3,4</sup> ,  
Sílvia Viñals <sup>5</sup> , Daniel Galaviz <sup>1,6</sup>  and Federico Herrera <sup>2,7,\*</sup> 

TISSUE REGENERATION



Cell proliferation



Improved cell viability




↓ Aβ / Tau

Coelho et al 2022

# Proton Therapy

- Finite range
- Minimal lateral scattering
- **Higher dose conformity**
- Advanced dose shaping capabilities
- **Higher precision**
- Lower integral dose
- **Reduced toxicity**



# OBJECTIVES

- Evaluate the capability of **PT** to **disrupt or diminish** the formation of **toxic protein amyloids** associated with neurodegenerative disorders
  - Study the effects of different types of **radiation** on the structure and conformation of those **toxic protein amyloids**
    - **Experimental validation** of the predicted results on abnormal deposits of protein amyloids
  - Optimize experimental conditions and develop an **irradiation protocol**
  - Characterization of the **biochemical** and **biophysical** mechanisms underlying the optimal **PT** conditions for **disruption of amyloid deposits**




# GAMMA-IRRADIATIONS

## Irradiation facility




PRECISA22 -  $^{60}\text{Co}$  irradiator used in the first experiments.




Dosimetric measurements of PRECISA22 performed with an ionizing chamber.


# Irradiation and protein extraction




# Detection of protein levels and aggregation



# Irradiation reduces the expression and aggregation of huntingtin




Representative Western blot of samples extracted from transfected HeLa cells 24 h after the irradiation.




Representative filter trap assay of 19Qhtt or 97Qhtt transfected HeLa cells after the irradiation with the referred doses.

# DEVELOPMENT OF THE IMP BEAM LINE FOR CELL IRRADIATION



# Exit window



- $\varnothing$  35 mm
- Al foil
  - 99% purity
  - 50  $\mu\text{m}$  thickness
- Vacuum test



Vacuum test of the larger exit window.

# Exit window


- TOPAS simulations



Results from the MC simulations with and without the aluminum foil in terms of fluence and energy fluence depending on the initial beam energy.

# HOMOGENEOUS IRRADIATION FOR PT STUDIES @ IMP

## RCF dosimetry system



EBT3 RCF's

$$D(Gy) = a + \frac{b}{PV - c}$$

Calibration equation (Sanchez-Parcerisa et al 2021)




# RCF dosimetry system

- Calibration

Parameter	<Red>	<Green>	<Blue>
a	$-1.59 \pm 0.88$	$-0.497 \pm 0.642$	$-3.12 \pm 0.60$
b	$89.4 \pm 23.0$	$78.9 \pm 18.8$	$227 \pm 33$
c	$58.6 \pm 1.3$	$26.9 \pm 4.2$	$27.1 \pm 1.6$




Calibration parameters.



Irradiation pattern of the calibration RCFs.


# RCF dosimetry system

- Calibration




Fitting of the pixel values (PV) in RGB with the defined calibration parameters

# RCF dosimetry system – time and distance




Calculated avDose in function of the exposure time and the distance to the exit window

# RCF dosimetry system - reproducibility




Calculated avDose for RCFs irradiated in the same conditions

# RCF dosimetry system – scanning area



Calculated Red Channel Dose in function of the scanning area

# RCF dosimetry system – beam intensity




Calculated avDose in function of the initially measured beam intensity for different distances to the exit window

# PROTON IRRADIATION OF CELLS


## Experimental conditions

- IMP beam line
- 10 MeV H<sup>+</sup>
- Large Al exit window ( $\varnothing = 35$  mm)
- Intensity = 0.9(1) nA
- Distance to the sample = 60 mm
- Area scanned with the raster = 75x75 mm<sup>2</sup>



# Online RCF analysis

- RCFs placed inside the 35 mm cell culture dish
  - $t = 5, 10$  and  $20$  s
- RCF placed inside the 96well plate
  - $t = 5, 10$  and  $20$  s
- Dose rate  $\approx 0.1$  Gy/s
  - 10 s to deliver 1 Gy







## RCF 24 h analysis

RCF ID	Placement	Planned time (s)	Real time (s)	Intensity (nA)	Dose rate (Gy/s)
RCF04	Outside 35 mm dish	5	7	0.91	0.06
RCF05	Inside 35 mm dish	5	7	0.93	0.1
RCF06		10	11	0.93	
RCF07		20	22	0.94	
RCF10	Outside 96 well plate	5	6	0.93	0.06
RCF12_1 <sup>st</sup>	Inside 96 well plate	5	7	0.93	0.06
RCF12_2 <sup>nd</sup>		10	12		0.1
RCF12_3 <sup>rd</sup>		30	32		
RCF12_4 <sup>th</sup>		30	32		
RCF12_5 <sup>th</sup>		10	12		
RCF12_6 <sup>th</sup>		5	7		0.06


# RCF 24 h analysis




RCF04




RCF05




RCF06



RCF07




RCF10



RCF12


# Biological samples irradiation

- 3 cell lines
  - STHdh Q7, STHdh Q111 and STHdh Q7/111
- 3 doses of radiation
  - 2, 5 and 10 Gy
- Irradiation in duplicate



Setup of the biological samples irradiation


# Biological samples irradiation



Internal charge measurements during the irradiation of the biological samples with 2, 5 and 10 Gy

# FUTURE WORK

- Analysis of the biological samples irradiated with the proton beam
- Irradiation of biological samples with a commercial linear accelerator used for medical purposes



- Monte Carlo simulations of radiation effects on the protein aggregates



# SUMMARY

- Effects of RT demonstrated with the preliminary experiments performed using  $\gamma$ -rays
  - Reduction in the expression and aggregation of proteins
- RCF dosimetry system is a reliable and easy to use method to calculate the dose rate
- Proton irradiation conditions with higher influence in dose delivery
  - Beam intensity
  - Scanning area
  - Time of exposure

# REFERENCES

- Crescenzi O, Tomaselli S, Guerrini R, Salvadori S, D'Ursi AM, Temussi PA, Picone D. 1IYT - Solution structure of the Alzheimer's disease amyloid beta-peptide (1-42). 2002. Available from: [RCSB PDB - 1IYT: Solution structure of the Alzheimer's disease amyloid beta-peptide \(1-42\)](#) [last accessed 25/11/2022].
- Hussain R, Zubair H, Pursell S, Shahab M. Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches. *Brain Sci.* 2018; 8(177).
- Coelho CM, Pereira L, Teubig P, Santos P, Mendes F, Viñals S, Galaviz D, Herrera F. Radiation as a Tool against Neurodegeneration—A Potential Treatment for Amyloidosis in the Central Nervous System. *International Journal of Molecular Sciences.* 2022; 23(20):12265. <https://doi.org/10.3390/ijms232012265>
- Samsung Medical Center. Principles of Proton Therapy. Available from: [How it works - What is Proton Therapy? - SAMSUNG PROTON THERAPY CENTER \(samsunghospital.com\)](#) [last accessed 25/11/2022].
- Sanchez-Parcerisa D, Sanz-García I, Ibáñez P, España S, Espinosa A, Gutiérrez-Neira C, López A, Vera JÁ, Mazal A, Fraile LM, Udías JM. Radiochromic film dosimetry for protons up to 10 MeV with EBT2, EBT3 and unlaminated EBT3 films. *Phys Med Biol.* 2021;66(115006).

# Thanks!

## Any questions?

cmcoelho@lip.pt

### **Acknowledgements:**

ProtoTera Grant - PRT/BD/151545/2021, Centre grants to BioISI – UIDB/04046/2020 and UIDP/04046/2020, Centre grants to LIP UIDB/50007/2020, UIDP/50007/2020 and LA/P/0016/2020.



# Support slides

Institution	Patients	Treatment	Outcome measures	Reference
University Hospital of Geneva	10 patients (observation) + 10 patients (LDRT)	10 Gy in 5 x 2 Gy (5 consecutive days)	PET scan (8-12 weeks) Neurocognitive tests (6 and 12 months) Treatment toxicity (12 months)	Zilli, T. 2021 (NCT03352258)
William Beaumont Hospitals	15 patients (arm 1) + 15 patients (arm 2)	10 Gy in 5 x 2 Gy (arm 1) 20 Gy in 10 x 2 Gy (arm 2)	PET scan (4 months) Neurocognitive tests and Treatment toxicity (6 weeks, 3, 6 and 12 months)	Fontanesi, J. 2022 (NCT02359864)
Kyung Hee University Hospital	5 patients (arm 1) + 5 patients (arm 2)	9 Gy in 5 x 1,8 Gy (arm 1) 5,4 Gy in 3 x 1,8 Gy (arm 2)	PET scan and neurocognitive tests (6 months)	Kyung Hee University Hospital at Gangdong 2020 (NCT04203121)
Virginia Commonwealth University	15 patients (arm 1) + 15 patients (arm 2)	10 Gy in 5 x 2 Gy (arm 1) 20 Gy in 10 x 2 Gy (arm 2)	Neurocognitive tests (6 weeks, 3, 6 and 12 months) Treatment toxicity (48 months)	Virginia Commonwealth University 2021 (NCT02769000)

# Support slides

Patient	Disease	Age (years)	Nr. of scans	Total administered dose (Gy)	Reference
1	AD	81	11	0,447	Cuttler et al. 2016, 2017, 2018, 2021
2	PD	n.a.	6	0,240	Cuttler et al. 2017
3	AD	88	4	0,165	Cuttler et al. 2021
4	AD	90	4	0,175	Cuttler et al. 2021
5	AD	84	4	0,162	Cuttler et al. 2021
6	AD	82	4	0,161	Cuttler et al. 2021

# Support slides

- RCF dosimetry system
  - LET quenching effect (Sanchez-Parcerisa et al 2021)
    - Surface energy at the film active layer

$$E_s(z, E_0) = \left[ (E_0 - sE_0^q)^p - \frac{z}{r} \right]^{1/p}$$

- Proton LET in film active layer

$$LET_{AL} = ae^{-bE_s} + ce^{-dE_s}$$

- Relative efficiency

$$RE(LET_{AL}) = 1 - A \cdot LET_{AL}^B,$$

# Support slides




Implantation line



Large exit window







# Support slides



## Support slides

	$a$ (keV $\mu\text{m}^{-1}$ )	$b$ (MeV $^{-1}$ )	$c$ (keV $\mu\text{m}^{-1}$ )	$d$ (MeV $^{-1}$ )
EBT3	$(4.1 \pm 1.5) \times 10^5$	$2.88 \pm 0.12$	$22.5 \pm 1.9$	$0.142 \pm 0.013$

# Support slides

Picture	avDose (Gy)	Irradiation time (s)	Dose rate (Gy/s)	Beam intensity (nA)	Distance to beam exit (mm)	Scanning area (mm <sup>2</sup> )
	$1.34 \pm 0.12$	2	0.67	0.8	40	40x40
	$2.78 \pm 0.25$	5	0.556	0.8	40	40x40
	$6.07 \pm 0.37$	10	0.607	0.8	40	40x40
	$8.53 \pm 0.40$	15	0.569	0.8	40	40x40
	$1.04 \pm 0.06$	2	0.52	0.8	60	40x40
	$2.71 \pm 0.22$	5	0.542	0.8	60	40x40